CYP11B1
ENSG00000160882
Target class
Enzyme
Chromosome
8
Approved drugs
4
Clinical candidates (approved and in development)
4
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Target name
- CYP11B1
- Gene name
- Cytochrome P450 family 11 subfamily B member 1
- Gene symbol
- CYP11B1
- Previous gene symbols
- CYP11B
- Protein name
- Cytochrome P450 11B1, mitochondrial (CYP11B1) (CYPXIB1) (Cytochrome P-450c11) (Cytochrome P450C11) (Steroid 11-beta-hydroxylase, CYP11B1) (EC 1.14.15.4)
- P450C11
- FHI
- CPN1
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 11
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 2
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 4,787.34
- Tissue specificity (Gini)
- 0.98
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:1584
- Protein interaction confidence
- 0.904321
- Protein interaction partners
- 28
- R-HSA-194002
- R-HSA-211976
- R-HSA-5579017
- End position
- 142880000
- Start position
- 142871528
- Chromosome
- 8
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein .
- Mitochondria
- Tissue specificity (tau)
- 0.999942
- Expression inequality (Gini)
- 0.980476
Expression in transcripts per million
- Adrenal Gland
- 4,787.34
- Testis
- 6.41
- Cervix - Ectocervix
- 0.86
- Fallopian Tube
- 0.54
- Bladder
- 0.48
Expression in transcripts per million
- Adrenal Gland4,787.34
- Testis6.41
- Cervix - Ectocervix0.86
- Fallopian Tube0.54
- Bladder0.48
- Ovary0.36
- Uterus0.35
- Spleen0.33
- Vagina0.3
- Esophagus - Mucosa0.29
- Pituitary0.27
- Brain - Cerebellum0.23
- Prostate0.23
- Kidney - Cortex0.23
- Small Intestine - Terminal Ileum0.21
- Stomach0.2
- Liver0.2
- Pancreas0.2
- Colon - Transverse0.18
- Cervix - Endocervix0.18
- Minor Salivary Gland0.18
- Esophagus - Muscularis0.18
- Brain - Cerebellar Hemisphere0.17
- Artery - Aorta0.16
- Kidney - Medulla0.16
And 29 more, listed on the interactive page.
- GO:0006700
- GO:0006704
- GO:0006955
- GO:0008217
- GO:0016125
- GO:0032342
- GO:0032870
- GO:0034651
- GO:0035865
- GO:0042593
- GO:0005739
- GO:0005743
- GO:0004507
- GO:0020037
Related records
Trials (74)
- A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
- A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
- A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus
- A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes
- A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function
- A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
- A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction
- A Safety and Feasibility Study of Mitotane in Prostate Cancer
- A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
- A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
- A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
- A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension
- Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals
- Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake
- Alternation in the Human Microbiome With Commonly Used Topical Medications
- An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known as Athlete's Foot
- Antiglucocorticoid Augmentation of antiDepressants in Depression
- Bioavailability of Levoketoconazole and Ketoconazole Tablets
- Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Drugs (5)
- Levoketoconazole Cytochrome P450 11B1 inhibitor
- Metyrapone Cytochrome P450 11B1, mitochondrial inhibitor
- Mitotane Cytochrome P450 11B1 inhibitor
- Osilodrostat Cytochrome P450 11B1 inhibitor
- Osilodrostat phosphate Cytochrome P450 11B1 inhibitor